中访网数据 山东金城医药集团股份有限公司今日公告，公司与英国女性健康药物公司Theramex HQ UK Limited签署了《权益许可和经销协议之补充协议1》，进一步深化双方在女性健康领域的战略合作。根据协议，金城医药新增获得利塞膦酸钠片(Actonel®)、利塞膦酸钠肠溶片(Actonel GR®)、雌二醇贴片(Evorel®)、雌二醇醋酸炔诺酮贴片(Evorel Conti®)及雌二醇贴片/雌二醇醋酸炔诺酮贴片组包装(Evorel Sequi®)共五款产品在中国大陆、香港及澳门地区的独家排他商业化权益。Theramex将继续作为产品在上述区域的上市许可持有人，金城医药则作为指定代理人，负责合作产品的注册、分销、市场推广及相关监管事务。此次合作是继2025年5月双方就雌二醇黄体酮软胶囊(Bijuva®)达成合作后的又一重要进展，旨在共同拓展中国绝经后妇女激素替代疗法及骨质疏松症治疗市场。公司表示，此举丰富了其在女性健康领域的产品管线，特别是Evorel Sequi®填补了国内雌孕激素连续序贯贴剂市场的空白，有助于提升公司在相关领域的品牌影响力。本次协议签署无需提交董事会及股东大会审议，不构成关联交易或重大资产重组，预计不会对公司本年度财务状况及经营业绩构成重大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.